Condition
Idiopathic Bronchiectasis
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed2
Not Yet Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07566611Not ApplicableNot Yet RecruitingPrimary
Primary Ciliary Dyskinesia in Adult Bronchiectasis
NCT04417777CompletedPrimary
Genetic Study of the Dilatations of the Idiopathic Bronchi in French Polynesia
NCT03750734Completed
Target Validation and Discovery in Idiopathic Bronchiectasis
NCT02061852Not ApplicableTerminated
Evaluation of the Safety of the Medical Device Simeox®
Showing all 4 trials